Controlled release of anticancer drug using o -phenylenediamine functionalized SBA-15 as a novel nanocarrier
- PDF / 1,365,904 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 21 Downloads / 211 Views
ORIGINAL PAPER
Controlled release of anticancer drug using o‑phenylenediamine functionalized SBA‑15 as a novel nanocarrier Leila Hajiaghababaei1 · Mahtab Eslambolipour1 · Alireza Badiei2 · Mohammad R. Ganjali3,4 · Ghodsi M. Ziarani5 Received: 29 August 2020 / Accepted: 5 November 2020 © Institute of Chemistry, Slovak Academy of Sciences 2020
Abstract In this study, a pH-sensitive drug delivery system was presented by o-phenylenediamine functionalized SBA-15 as a new carrier for controlled release of imatinib mesylate. O-phenylenediamine functionalized SBA-15 mesoporous silica was synthesized and characterized. Powder X-ray diffraction proved the 2D hexagonal mesostructure with p6mm space group for nanoporous materials. The o-phenylenediamine functionalized SBA-15 showed the BET surface area 265 m2g−1 and pore diameter 5.8 nm, based on adsorption–desorption of N2 at 77 ºK. The presence of organic groups in the silica framework was demonstrated by FTIR spectrum. Then, the imatinib mesylate was loaded on o-phenylenediamine functionalized SBA-15 in saturated drug aqueous solution at ambient temperature for 1 h. According to the observations on drug release in phosphate buffers, the imatinib mesylate release from o-phenylenediamine functionalized SBA-15 shows a pH-associated behavior, and the rate of imatinib mesylate release was quicker at lower pH than higher pH. In addition, the imatinib mesylate had a slow release pattern in SBF with a constant rate of approximately 1.4 µg h−1 after the first hour. The results illustrated that o-phenylenediamine functionalized SBA-15 is a suitable option for being employed as a new carrier for controlled release of imatinib mesylate. Keywords Controlled release · Functionalized SBA-15 · Imatinib mesylate · Nanocarrier · o-phenylenediamine · pH-sensitive
Introduction The controlled release is required in administration of toxic anti-cancer drugs that must not have contact with healthy tissue. Controlled release of the drug at an optimal rate offers various advantages compared to the conventional dosage * Leila Hajiaghababaei [email protected] 1
Department of Chemistry, Yadegar‑e‑Imam Khomeini (RAH) Shahre Rey Branch, Islamic Azad University, Tehran, Iran
2
School of Chemistry, College of Science, University of Tehran, Tehran, Iran
3
Center of Excellence in Electrochemistry, School of Chemistry, College of Science, University of Tehran, Tehran, Iran
4
Biosensor Research Center, Endocrinology and Metabolism Molecular‑Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
5
Department of Chemistry, Alzahra University, Tehran, Iran
form. In a controlled release system, the whole drug dose for a specific period is delivered once, and it is released in a controlled way, which improves patient compliance. Besides, the drug release is done at a constant rate and the blood concentration of the drug stays steady (Fathi Vavsari et al. 2015), which enhances its efficacy. Reduced harmful side effects and protection against rapid me
Data Loading...
